Gene therapy biopharma uniQure sets terms for $64 million IPO

By
A A A

uniQure, which develops gene therapies for the treatment of orphan diseases, announced terms for its IPO on Friday. The Amsterdam, Netherlands-based company plans to raise $64 million by offering 4.6 million shares at a price range of $13 to $15. At the midpoint of the proposed range, uniQure would command a market value of $235 million.

uniQure, which was founded in 1998 and booked $3 million in license and collaboration revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol QURE. uniQure initially filed confidentially on November 8, 2013. Jefferies, Leerink Partners and Piper Jaffray are the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: QURE

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

55,414,702
  • $15.38 ▼ 0.39%
38,503,210
  • $66.34 ▲ 2.26%
36,466,704
  • $8.36 ▼ 9.52%
35,253,294
  • $26.55 ▲ 1.34%
32,752,347
  • $6.55 ▲ 1.87%
31,778,001
  • $95.22 ▲ 0.19%
28,396,556
  • $51.49 ▼ 0.62%
23,800,987
  • $42.09 ▲ 0.97%
As of 7/11/2014, 04:03 PM